Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1981 1
1982 1
1983 2
1985 2
1987 1
1988 4
1989 6
1990 2
1991 4
1992 2
1993 8
1994 2
1995 6
1996 6
1997 7
1998 3
1999 5
2000 2
2001 5
2002 5
2003 6
2004 8
2005 10
2006 12
2007 11
2008 13
2009 11
2010 17
2011 15
2012 9
2013 19
2014 22
2015 15
2016 12
2017 21
2018 33
2019 33
2020 37
2021 35
2022 38
2023 40
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

454 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Kim PS, Fishman MA. Kim PS, et al. Curr Pain Headache Rep. 2020 Aug 26;24(10):64. doi: 10.1007/s11916-020-00898-0. Curr Pain Headache Rep. 2020. PMID: 32845365
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose naltrexone in the treatment of chronic pain. RECENT FINDINGS: Recent pre-clinical uses and clinical studies further elucidate th …
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose …
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K, Vrooman B. Toljan K, et al. Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.
A dosing range between 1 mug and 1 mg comprises very low-dose naltrexone (VLDN), which has primarily been used as an experimental adjunct treatment for boosting tolerability of opioid-weaning methadone taper. In general, all of the low-dose feat …
A dosing range between 1 mug and 1 mg comprises very low-dose naltrexone (VLDN), which has primarily been used as an ex …
Low-Dose Naltrexone in Rheumatological Diseases.
de Carvalho JF, Skare T. de Carvalho JF, et al. Mediterr J Rheumatol. 2023 Mar 31;34(1):1-6. doi: 10.31138/mjr.34.1.1. eCollection 2023 Mar. Mediterr J Rheumatol. 2023. PMID: 37223594 Free PMC article. Review.
BACKGROUND: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) has been used in several diseases including chronic pain and autoimmune conditions, including rheumatic disorders. ...
BACKGROUND: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) h …
Low Dose Naltrexone in the Treatment of Fibromyalgia.
Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Metyas S, et al. Curr Rheumatol Rev. 2018;14(2):177-180. doi: 10.2174/1573397113666170321120329. Curr Rheumatol Rev. 2018. PMID: 28325149 Clinical Trial.
It is hypothesized that low dose naltrexone causes transient blockade of opioid receptors centrally resulting in a rebound of endorphin function which may attenuate pain in fibromyalgia. RESULTS: Two small prospective pilot studies have previously shown that …
It is hypothesized that low dose naltrexone causes transient blockade of opioid receptors centrally resulting in a rebo …
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Li Z, You Y, Griffin N, Feng J, Shan F. Li Z, et al. Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7. Int Immunopharmacol. 2018. PMID: 29885638 Review.
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and signi …
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to …
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
Patten DK, Schultz BG, Berlau DJ. Patten DK, et al. Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. Pharmacotherapy. 2018. PMID: 29377216 Review.
Currently, evidence supports the safety and tolerability of low-dose naltrexone in multiple sclerosis, fibromyalgia, and Crohn's disease. ...These studies do demonstrate that low-dose naltrexone has subjective benefits over placebo, but e …
Currently, evidence supports the safety and tolerability of low-dose naltrexone in multiple sclerosis, fibromyalgia, an …
Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review.
Rupp A, Young E, Chadwick AL. Rupp A, et al. Pain Med. 2023 Nov 2;24(11):1270-1281. doi: 10.1093/pm/pnad074. Pain Med. 2023. PMID: 37302106 Free PMC article. Review.
BACKGROUND: At low doses, naltrexone (LDN) has been shown to modulate inflammation through the interruption of microglial cell activation within the central nervous system. ...
BACKGROUND: At low doses, naltrexone (LDN) has been shown to modulate inflammation through the interruption of microglial cell activa …
Low-dose naltrexone as a treatment for chronic fatigue syndrome.
Bolton MJ, Chapman BP, Van Marwijk H. Bolton MJ, et al. BMJ Case Rep. 2020 Jan 6;13(1):e232502. doi: 10.1136/bcr-2019-232502. BMJ Case Rep. 2020. PMID: 31911410 Free PMC article.
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn's disease, fibromyalgia and …
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although …
The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review.
Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, Bauer BA, Mohabbat AB. Yang J, et al. J Pain Res. 2023 Mar 21;16:1017-1023. doi: 10.2147/JPR.S395457. eCollection 2023. J Pain Res. 2023. PMID: 36974308 Free PMC article. Review.
Fibromyalgia (FM) is a chronic pain sensitivity syndrome characterized by diffuse musculoskeletal pain and many other systemic manifestations. Low-dose naltrexone (LDN) has been increasingly used as an off-label treatment option in FM. ...Overall, LDN was fou …
Fibromyalgia (FM) is a chronic pain sensitivity syndrome characterized by diffuse musculoskeletal pain and many other systemic manifestation …
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J, Parkitny L, McLain D. Younger J, et al. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Clin Rheumatol. 2014. PMID: 24526250 Free PMC article. Review.
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory ag …
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's …
454 results

Searches related to "low-dose naltrexone"